Berkeley Lights, Inc., a life sciences instruments firm, at the moment introduced the launch of the Beacon Choose™, the corporate’s new optofluidic system for cell line improvement (CLD). The Beacon Choose builds upon the identical cutting-edge know-how supplied by the unique Beacon system launched in 2017 that at present has an put in base of greater than 130 programs globally. The Beacon Choose gives clients optofluidic and NanoPen® chamber know-how and propriety CLD functions, however with the optimum stage of options to satisfy the analysis and budgetary wants for brand spanking new market section clients.
Beacon Choose is a two-chip, single-cell optofluidic system for CLD that allows scientists to clone, tradition, assay and choose high clones in a single run on a single platform and ideally fitted to small- to mid-sized biopharma and CDMOs/CROs. This contrasts with the preliminary four-chip Beacon system enabled for antibody discovery and CLD, geared towards high-campaign utilization from massive biopharma and established CDMOs/CROs. The Beacon Choose allows excessive throughput cloning, screening, and choice of top-performing CHO cell traces in simply days utilizing the Opto® CLD workflow. As well as, the Opto® Guarantee Assays allow customers to pick clones with favorable product high quality attributes inside 5 days of cloning to scale back general bioprocessing prices, enhance the chance of success, and additional shorten timelines by deciding on increased high quality clones for scale up.
To extend buyer accessibility and affordability, Berkeley Lights will provide Beacon Choose with completely different buy choices together with capital placement, lease, or reagent rental. The 2-chip Beacon Choose record value will likely be roughly half of the present Beacon system, which makes the know-how very best for brand spanking new customers that don’t want the complete Beacon capability. As well as, this cheaper price level permits current CLD Beacon clients to extend throughput and current Antibody Discovery Beacon clients to entry CLD functions.
“Berkeley Lights is enhancing its strategy to the market with the introduction of a extra versatile configuration and pricing fashions that’s targeted on clients’ whole price of possession,” mentioned Siddhartha Kadia, Ph.D., chief govt officer of Berkeley Lights.
The Beacon Choose is the primary in a collection of recent platform launches that present decrease obstacles to entry for patrons to accumulate our game-changing know-how targeted on cell line improvement. By the second half of 2023, we may also provide Beacon Quest an optofluidic system specialised for tutorial analysis institutes and translational analysis facilities.”
Siddhartha Kadia, Ph.D., Chief Government Officer, Berkeley Lights
Extra options and advantages of the Beacon Choose
The Beacon Choose system can:
- Choose clones with increased titers than conventional strategies
- Enhance throughput by 2x whereas decreasing cell line improvement timelines by as much as 50%
- Obtain cloning efficiencies 5x higher than FACS and 10x higher than limiting dilution, whereas recovering clones with >99% monoclonality assurance
- Make the most of the brand new Berkeley Lights’ Customized Productiveness Assay that allows choice of clones secreting all kinds of molecules, together with antibodies, protein-based vaccines, enzymes, fusion proteins, antibody fragments, and cytokines. This functionality permits all kinds of initiatives to be accomplished on a single instrument.
